IDEXX Laboratories Shares Slip 1.18% to $458.06 on Mixed Trading Day
June 21, 2023
☀️Trending News
IDEXX ($NASDAQ:IDXX) Laboratories Inc. experienced a decline in shares on Thursday, as the stock market had a mixed day of trading. Shares of the diagnostics and software solutions company slipped 1.18% to $458.06. IDEXX Laboratories Inc. is an innovative, global leader in diagnostics and software solutions for the veterinary, livestock, and poultry industry. Their products provide veterinarians, farmers, and pet owners with diagnostic and information technology-based solutions which improve animal health, increase productivity, and enhance the quality of their lives. They have a wide array of products including veterinary diagnostics, laboratory instruments, software, service programs, and pet healthcare services.
Additionally, IDEXX is dedicated to providing quality customer service and support to customers around the world.
Analysis
At GoodWhale, we have conducted an analysis of IDEXX LABORATORIES‘ fundamentals. After an in-depth analysis of the company’s financial statements and other pertinent information, we have determined that based on our risk rating, IDEXX LABORATORIES is a high risk investment. We have identified four distinct risk warnings across the income sheet, balance sheet, cash flow statement, and non-financial aspects. In order to gain full access to our analysis and the associated risk warnings, you must register with GoodWhale. Once registration is complete, you will be able to view our complete findings and use our platform to make more informed investment decisions. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Idexx Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 3.43k | 699.18 | 20.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Idexx Laboratories. More…
| Operations | Investing | Financing |
| 612.19 | -193.02 | -503.54 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Idexx Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.81k | 1.97k | 7.34 |
Key Ratios Snapshot
Some of the financial key ratios for Idexx Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.8% | 18.2% | 27.2% |
| FCF Margin | ROE | ROA |
| 13.3% | 95.7% | 20.7% |
Peers
The company’s main competitors are NeoGenomics Inc, SQI Diagnostics Inc, and Genetic Technologies Ltd. All three companies offer similar products and services, but IDEXX Laboratories Inc has the largest market share.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics is a cancer-focused company that provides testing and services related to the diagnosis and treatment of cancer. The company has a market cap of 956.68M as of 2022 and a Return on Equity of -3.79%. NeoGenomics offers a variety of services including genetic testing, molecular testing, and immunohistochemistry. The company also provides consultative services to oncologists and pathologists.
– SQI Diagnostics Inc ($TSXV:SQD)
SQI Diagnostics Inc. is a global provider of multiplexing diagnostic solutions. The company offers a range of products and services that are used in the early detection, diagnosis, and prognosis of disease. Its products are used in a variety of settings, including hospitals, clinics, and research laboratories. SQI Diagnostics Inc. has a market cap of 61.01M as of 2022. The company’s Return on Equity is -1578.51%. SQI Diagnostics Inc. is a global provider of multiplexing diagnostic solutions. The company offers a range of products and services that are used in the early detection, diagnosis, and prognosis of disease.
– Genetic Technologies Ltd ($ASX:GTG)
As of 2022, Genetic Technologies Ltd has a market cap of 27.7M and a Return on Equity of -23.54%. The company is involved in the development and commercialization of genetic testing products and services. Its products are used for the early detection of cancer and other diseases.
Summary
IDEXX Laboratories Inc. experienced a decline of 1.18% in its stock price on Thursday, closing at $458.06. Overall, the stock market was mixed on the day, with investors uncertain of the stock’s performance. Analysts generally consider IDEXX Laboratories a solid investment opportunity. It has a strong record of sales growth and has outperformed the market in recent quarters.
Investors should consider IDEXX Laboratories’ long-term potential, as well as its short-term volatility, when making decisions. Analysts recommend a strategy that takes into account the company’s solid fundamentals and its robust financials.
Related Posts
Recent Posts
